Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:

• Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00)
  • Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract 
  • Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01.
• Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00)
  • Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract
• Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25)
  • Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract
• Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57)
  • Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5.

CME information and select publications

Featuring perspectives from Dr Ramaswamy Govindan and Dr Stephen V Liu, including the following topics:

• Introduction (0:00)
• Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation — Dr Govindan (4:04)
• First- and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation — Dr Liu (26:59)

CME information and select publications

Featuring perspectives from Dr Christopher Lieu and Dr Kanwal Raghav, including the following topics:

• Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Dr Lieu (0:00)
• Recent Advances in the Management of Metastatic CRC — Dr Raghav (32:58)

CME information and select publications

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics:

• Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00)
• Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50)
• Published Clinical Data Involving Axi-cel (10:24)
• Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34)
• Published Clinical Data Involving Tis-cel (19:47)
• Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43)
• Published Clinical Data Involving Liso-cel (26:05)
• Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48)
• Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35)
• Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59)

CME information and select publications

Featuring perspectives from Dr Emmanuel S Antonarakis and Prof Karim Fizazi, including the following topics:

• Introduction: Quality of Life (0:00)
• PARP Inhibition (PARPi) (7:15)
• M0 Disease (23:18)
• Metastatic Hormone-Sensitive Prostate Cancer (34:33)
• Radiopharmaceuticals (46:16)
• Other Novel Investigational Approaches for Metastatic Castration-Resistant Prostate Cancer (54:53)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches — Emmanuel S Antonarakis, MD

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer (PC) — Professor Karim Fizazi, MD, PhD

CME information and select publications

Featuring perspectives from Dr Christopher Flower and Dr Krish Patel, including the following topics:

• Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Non-Hodgkin Lymphoma (NHL) — Dr Patel (0:00)
• Other Available and Emerging Novel Therapies for NHL — Dr Flowers (22:07)

CME information and select publications

Featuring perspectives from Dr David M O'Malley and Dr Brian M Slomovitz, including the following topics:

• Ovarian Cancer; HER2-Directed Therapy for Advanced Gynecologic Cancers — Dr O'Malley (0:00)
• Endometrial Cancer and Cervical Cancer — Dr Slomovitz (23:38)

CME information and select publications

Featuring an interview with Dr John P Leonard, including the following topics:

• First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00)
• Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27)
• Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30)
• Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24)
• Practical considerations for the administration of mosunetuzumab (22:03)
• Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33)
• Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27)
• Risk of infection for patients receiving bispecific antibodies (33:23)
• Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21)
• Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23)
• Myths and misperceptions about the management of DLBCL, FL and MCL (47:29)

CME information and select publications